What is radiofrequency ablation and how does COOLIEF work for knee pain?

Radiofrequency (RF) ablation uses controlled radio wave energy to heat nerve tissue, disrupting the nerve's ability to transmit pain signals — without destroying the nerve's function for other sensations. For chronic knee pain from osteoarthritis, the genicular nerves (nerves that transmit pain sensation from the knee joint) are targeted with RF ablation through needles placed under imaging guidance. Conventional RF ablation (non-cooled) creates a small localized heat lesion at the needle tip; COOLIEF's 'cooled' radiofrequency technology circulates water through the probe to cool the tip while heating surrounding tissue from inside out — this creates a larger ablation zone that can more reliably target the genicular nerves. A COOLIEF procedure can provide knee pain relief for 6-12+ months, potentially delaying or avoiding total knee replacement surgery for patients who are not yet surgical candidates or who wish to defer surgery. COOLIEF is performed in pain management clinics and orthopedic offices as an outpatient procedure.

What is the aesthetic injectables market and why is Botox so dominant?

The aesthetic injectables market consists of two main categories: neurotoxins (botulinum toxin for wrinkle relaxation — Botox, Dysport, Xeomin, Jeuveau, Daxxify) and dermal fillers (hyaluronic acid and other materials for volume replacement — Juvederm, Restylane, Sculptra, Radiesse). The U.S. aesthetic neurotoxin market is approximately $2-3 billion annually and growing as consumers of all ages adopt injectable aesthetics. Botox's dominance (approximately 60-70% U.S. neurotoxin market share) comes from: 30+ year track record as the original FDA-approved cosmetic neurotoxin creating the category; deep physician training programs and injector loyalty built over decades; brand recognition — 'Botox' has become a genericized term for neurotoxin procedures in popular culture; comprehensive portfolio (therapeutic Botox Therapeutic and cosmetic Botox Cosmetic) giving AbbVie leverage in purchasing negotiations; and Allergan/AbbVie's massive commercial infrastructure. Competing against Botox requires injectors to switch their preferred technique, relearn dosing, and risk patient dissatisfaction with a new product — high friction that explains why Dysport has had 15+ years to compete but achieved only ~15% market share.

What is enhanced recovery after surgery (ERAS) and how does ON-Q fit into it?

Enhanced Recovery After Surgery (ERAS) is an evidence-based multimodal perioperative care protocol designed to reduce surgical stress, maintain physiological function, and accelerate recovery. ERAS bundles multiple interventions: preoperative patient education and optimization; minimizing fasting before surgery; administering carbohydrate drinks before procedures; using regional anesthesia instead of general anesthesia when possible; using non-opioid multimodal pain management; early mobilization (walking within hours of surgery); early oral feeding; and avoiding nasogastric tubes. ERAS protocols have been shown to reduce hospital length of stay by 1-3 days, reduce complications, and lower opioid consumption. The opioid crisis has intensified focus on non-opioid pain management components of ERAS. ON-Q pain management systems deliver continuous local anesthetic through a catheter placed near the surgical site — avoiding systemic opioid use for post-surgical pain. ON-Q is used in orthopedic surgeries (hip, knee, shoulder replacement), abdominal and thoracic surgeries, and other procedures where regional nerve blocks can replace opioid analgesics for several days post-operatively.

brimindinvest.com / compare / rvnc-vs-avnsLIVE

RVNC

Revance Therapeutics, Inc. · Healthcare - Pharmaceuticals & Aesthetics

N/A

N/A this month

VERSUS

⟷

COMPARE

AVNS

Avanos Medical, Inc. · Healthcare - Medical Devices

$24.94

+0.77% this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

RVNC

0

AVNS

0

MIXED SETUP

Comparison scoreboard

MIXED SETUP

AI Score

RVNC N/A

AVNS 24.5

1Y Return

RVNC N/A

AVNS +106.46%

Fwd P/E

RVNC N/A

AVNS 19.95

Target Up.

RVNC N/A

AVNS N/A

Op. Margin

RVNC N/A

AVNS N/A

Metrics last refreshed: 6/20/2026

Quick take

RVNC vs AVNS Stock Comparison: AI Score, Valuation, Performance and Upside

RVNC (Revance Therapeutics) and AVNS (Avanos Medical) are both small-to-mid-cap healthcare companies in specialty markets — Revance is a commercial-stage biotech attempting to disrupt AbbVie's Botox dominance with longer-lasting Daxxify in the aesthetic neurotoxin market, while Avanos is a medical device company selling pain management and respiratory products to hospitals with a niche but established commercial presence. Both face competitive challenges but in very different medical specialty markets.

RVNC vs AVNS is aesthetic neurotoxin challenger disrupting Botox with longer duration innovation (Revance's Daxxify targeting the massive botulinum toxin market with a genuinely differentiated 6-month product competing against AbbVie's Botox dominance) versus niche medical device company with chronic pain and respiratory products (Avanos's COOLIEF and ON-Q serving post-surgical pain management and knee osteoarthritis with established hospital distribution but limited scale) — commercial biotech disruption attempt versus steady niche device business.

Live analysis · updated 6/20/2026

RVNC and AVNS are closely matched — they split the tracked metrics evenly.

Normalized 1Y performance

RVNC

AVNS

Not enough data to chart yet.

Recent returns

RVNC

AVNS

Analyst price targets & sentiment

RVNC

Price target data unavailable

N/A

AVNS

Price target data unavailable

N/A

Who should consider this stock?

RVNC may suit investors who:

→Believe Daxxify's 6-month duration is a clinically meaningful differentiation that can capture meaningful aesthetic neurotoxin market share from Botox despite the challenge of displacing a dominant incumbents with deep market relationships
→Accept Revance's pre-profitability and commercial ramp risk as typical of biotech companies building new therapeutic franchises against established competitors
→Value the therapeutic pipeline (cervical dystonia, spasticity) as providing revenue diversification beyond aesthetics if Daxxify's therapeutic label expands into additional neurological indications

AVNS may suit investors who:

→Want a commercial-stage medical device company with established hospital sales infrastructure in pain management — COOLIEF and ON-Q serve real clinical needs and have existing revenue
→See potential strategic value in Avanos as an acquisition target for a larger pain management or medical device company seeking to bolt on its established product portfolio and hospital customer relationships
→Value Avanos's relatively lower valuation versus commercial-stage biotechs as providing limited downside for a company with existing revenue and hospital market presence

Performance & AI score

Metric	RVNC	AVNS
AI score	N/A	24.5
AI rank	N/A	#3090
Latest close	N/A	$24.94
1M return	N/A	+0.77%
6M return	N/A	+113.71%
1Y return	N/A	+106.46%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

Period	RVNC	AVNS
1Y ago	N/A	$20.65K (+106.5%) started 2025-06-18
5Y ago	N/A	$6.27K (-37.3%) started 2021-06-18
10Y ago	N/A	$7.52K (-24.8%) started 2016-06-20

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Metric	RVNC	AVNS
Market cap	N/A	$1.17B
Trailing P/E	N/A	N/A
Forward P/E	N/A	19.95
Price/Sales	1.63	1.63
EV/Revenue	N/A	1.73
Analyst target	N/A	N/A
Target upside	N/A	N/A

Growth, profitability & risk

Metric	RVNC	AVNS
Revenue growth	N/A	8.80%
Earnings growth	N/A	-21.70%
EPS growth	N/A	-21.70%
FCF margin	N/A	+2.38%
Operating margin	N/A	N/A
Profit margin	N/A	-10.39%
ROIC proxy	N/A	-9.18%
Return on equity	N/A	-9.18%
Dividend yield	N/A	0.00%
Beta	-0.47	1.57
Debt/equity	N/A	17.70
Current ratio	N/A	2.48
Quick ratio	N/A	1.28

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

RVNC max drawdownN/A

AVNS max drawdown21.01%

RVNC max wkly dropN/A

AVNS max wkly drop16.54%

5Y risk snapshot

RVNC max drawdownN/A

AVNS max drawdown75.31%

RVNC max wkly dropN/A

AVNS max wkly drop21.52%

10Y risk snapshot

RVNC max drawdownN/A

AVNS max drawdown86.39%

RVNC max wkly dropN/A

AVNS max wkly drop28.23%

Performance metrics by period

Period	Metric	RVNC	AVNS
1Y	Growth	N/A	+106.46%
	CAGR	N/A	+106.56%
	Sharpe ratio	N/A	1.17
	Max drawdown	N/A	21.01%
	Max daily drop	N/A	12.09%
	Max wkly drop	N/A	16.54%
5Y	Growth	N/A	-37.26%
	CAGR	N/A	-8.90%
	Sharpe ratio	N/A	-0.08
	Max drawdown	N/A	75.31%
	Max daily drop	N/A	17.90%
	Max wkly drop	N/A	21.52%
10Y	Growth	N/A	-24.79%
	CAGR	N/A	-2.81%
	Sharpe ratio	N/A	0.04
	Max drawdown	N/A	86.39%
	Max daily drop	N/A	21.67%
	Max wkly drop	N/A	28.23%

Business comparison

Category	RVNC	AVNS
Company	Revance Therapeutics, Inc.	Avanos Medical, Inc.
Sector	Healthcare - Pharmaceuticals & Aesthetics	Healthcare - Medical Devices
Industry	N/A	N/A
Core business	Revance Therapeutics is a biotechnology company focused on neuromodulator (botulinum toxin) therapies — with its primary product Daxxify (DaxibotulinumtoxinA) FDA-approved for glabellar lines (forehead frown lines) in aesthetics and cervical dystonia (a neurological condition causing involuntary neck muscle contractions) in therapeutics. Daxxify's differentiator is its longer duration of effect — approximately 6 months versus 3-4 months for Botox Cosmetic — due to Revance's proprietary peptide exchange technology that stabilizes the toxin without human serum albumin.	Avanos Medical (formerly Halyard Health, spun off from Kimberly-Clark in 2014) is a medical device company focused on pain management and respiratory health. Avanos's core business includes: ON-Q pain management system (continuous nerve block pain pumps delivering local anesthetics post-surgery for enhanced recovery); COOLIEF cooled radiofrequency ablation for chronic knee pain; respiratory health devices including suction systems and enteral feeding; and PREVENA negative pressure wound therapy. Avanos serves acute care hospitals and outpatient procedures.
Investor focus	Investors track Daxxify commercial launch execution (converting aesthetic injectors from Botox to Daxxify), aesthetic market penetration against AbbVie's dominant Botox and Galderma's Dysport, therapeutic cervical dystonia revenue, Revance's RHA Collection dermal fillers (acquired through Teoxane partnership), and path to profitability as a commercial-stage biotech.	Investors track Avanos's pain management segment revenue (particularly COOLIEF and ON-Q growth), portfolio rationalization (divesting non-core product lines), margins and cost efficiency, and strategic alternatives as a sub-$1B market cap medical device company competing in fragmented markets.

RVNC strengths

→Daxxify's longer duration differentiates versus Botox — a 6-month interval between treatments versus 3-4 months means patients make fewer injector visits annually; this convenience advantage resonates with patients who find quarterly Botox maintenance inconvenient
→Proprietary peptide formulation platform with no human serum albumin — Revance's toxin formulation doesn't use human serum albumin (a blood-derived protein used in Botox); this purity profile and novel stabilization technology demonstrate genuine pharmaceutical innovation
→Therapeutic neuromodulator pipeline beyond aesthetics — Daxxify's therapeutic approval in cervical dystonia and ongoing clinical trials in other therapeutic areas (upper limb spasticity, plantar fasciitis) create potential revenue diversification beyond aesthetics

AVNS strengths

→COOLIEF cooled radiofrequency ablation addresses the large chronic knee pain market — COOLIEF uses cooled RF technology to ablate the genicular nerves providing sensation to the knee joint; this minimally invasive procedure provides pain relief for knee osteoarthritis patients before or as an alternative to total knee replacement
→ON-Q pain pump reduces opioid use post-surgery — enhanced recovery after surgery (ERAS) protocols increasingly prioritize non-opioid pain management; ON-Q's continuous nerve block catheters deliver local anesthetics directly to surgical sites, reducing opioid needs and improving recovery times
→Established hospital relationships and distribution infrastructure — Avanos has long-standing hospital sales relationships from the Halyard Health era; this infrastructure provides a distribution channel for its pain management and respiratory health products

Risks to watch — RVNC

→Competing against AbbVie's Botox is extraordinarily difficult — Botox has 30+ year market leadership, deep injector relationships, comprehensive training programs, and a powerful commercial sales force; displacing Botox market share requires persistent convincing of trained injectors to change their injection technique, product choice, and patient communication
→Slow aesthetic market penetration despite efficacy differentiation — uptake of Daxxify has been slower than Revance originally projected; convincing injectors to switch products when Botox is 'good enough' requires overcoming inertia; results have been commercially disappointing versus initial guidance
→Balance sheet and runway risk — Revance is pre-profitability and burns significant cash on commercial expansion and R&D; capital requirements to fund the full commercial buildout and therapeutic pipeline require ongoing financing that dilutes shareholders or strains the balance sheet

Risks to watch — AVNS

→Small market cap limits R&D investment and scale — Avanos's sub-$1B market cap constrains its ability to invest in new product development, clinical trials, and commercial infrastructure compared to larger device competitors
→Portfolio fragmentation across pain management and respiratory makes clear strategic narrative difficult — Avanos spans several product categories without the scale to be a category leader in any single one; investors may prefer pure-plays in each segment
→Chronic pain market competition — COOLIEF competes with multiple RF ablation systems from Medtronic, Boston Scientific, and others; ON-Q competes with elastomeric pumps; neither product holds a dominant market position

Frequently asked questions

Botulinum toxin is a neurotoxin produced by the bacterium Clostridium botulinum that temporarily blocks the nerve signals that cause muscle contractions. When injected in small amounts, it relaxes specific muscles — in aesthetics, this smooths dynamic wrinkles (frown lines, crow's feet, forehead lines) caused by repeated facial muscle contractions; in therapeutics, it treats conditions like cervical dystonia, chronic migraines, hyperhidrosis (excessive sweating), and overactive bladder by relaxing hyperactive muscles. Botox Cosmetic (AbbVie's onabotulinumtoxinA) has been the dominant product since FDA approval for cosmetics in 2002, with effects typically lasting 3-4 months before patients need reinjection. Daxxify (daxibotulinumtoxinA) uses a proprietary peptide excipient technology that binds to the toxin and extends its duration of action to approximately 6 months on average in clinical trials. This duration advantage means patients may need only 2 treatments per year versus Botox's 3-4 — a significant convenience benefit for regular users of aesthetic neurotoxins.

AI Prediction SignalNext 5 trading days

Members only

RVNC

+2.8%BUY

AVNS

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides